Journal of Psychoactive Drugs
September 23, 2026
Omer A. Syed, Rotem Petranker, Sean M. Nestor et al.
The use of ketamine as a treatment for mood disorders continues to grow in popularity. However, the differences between individuals consuming ketamine within clinical settings and those self-medicating in casual, non-clinical settings has not been yet characterized. Using the 2023 Global Psychedelic Survey, this study aimed to examine the demographic and clinical characteristics, as well as the...
Discovery medicine
September 23, 2026
Jozélio Freire de Carvalho, Eduardo Pondé de Sena
Background: Treatment-resistant depression (TRD) represents a major clinical challenge, being associated with high morbidity, increased suicide risk, and substantial socioeconomic burden. The need for rapidly acting interventions has driven the development of rapid-acting antidepressants (RAADs), such as ketamine, esketamine, and scopolamine. This study aimed to systematically review the...
International Immunopharmacology
September 22, 2026
Hanxuan Wang, Yu Huang, Qingwen Hu et al.
Schizophrenia (SCZ) is a serious neuropsychiatric disorder with a complex etiology. Neuroinflammation has received much attention as a crucial contributor to the pathogenesis of SCZ. S-propargyl-L-cysteine (SPRC), a synthesized analog of S-allyl-L-cysteine, increases endogenous hydrogen sulfide (H2S) synthesis and exerts potent antioxidative and anti-inflammatory effects. However, its potential...
npj Mental Health Research
September 22, 2026
Ramūnas Janavičius
The letter addresses critical issues in the methodology and conclusions of the meta-analysis, including inconsistencies in study design, methodological flaws in comparing correlation coefficients, and discrepancies in reported results and their interpretation. It contributes significantly to the ongoing discussion on psychedelic-assisted therapies and highlights the need for more standardized...
npj Mental Health Research
September 22, 2026
Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen et al.
This response addresses methodological concerns raised regarding our meta-analysis of subjective effects and therapeutic outcomes following ketamine and psilocybin treatment. We discuss the potential influence of psychotherapy and differences in subjective-effect questionnaires across studies, acknowledging these as important limitations. We argue that these factors may partly explain observed...
Journal of the Academy of Consultation-Liaison Psychiatry
September 21, 2026
Bo Hu, Alfonso Ortiz-Cruz, Ridhaa Sachidanandan et al.
Ketamine is an emerging therapy in psychiatry, but its implementation in the general hospital setting remains limited due to monitoring requirements, personnel allocation, and safety concerns in medically complex patients. Consultation-liaison (C-L) psychiatry services are well-positioned to deliver such interventions, yet practical models for doing so are lacking. To describe the...
Neuropsychopharmacology
September 21, 2026
Balwinder Singh, Hossam M Ali, Alessandro Miola et al.
Disrupted excitation-inhibition (E/I) balance involving GABA and glutamate (Glu) is implicated in the pathophysiology of depression. Ketamine, an NMDA receptor antagonist with rapid antidepressant properties, may modulate this balance, yet proton magnetic resonance spectroscopy (¹H-MRS) studies report inconsistent findings regarding the direction, magnitude, and timing of neurochemical effects....
bioRxiv (Cold Spring Harbor Laboratory)
September 21, 2026
Judith Kunze, Justus Student, Sarah Tune et al.
preprint
Non-invasive proxies of cortical excitation--inhibition (E:I) balance, are increasingly used to understand human neural dynamics; especially so the aperiodic (1/f) electroencephalographic (EEG) exponent. Ketamine, an NMDA-receptor antagonist, is thought to shift this balance toward excitation. Propofol, a GABAA-receptor agonist, should behave oppositely. Here we show that these pharmacological...
Frontiers in Psychiatry
September 21, 2026
Phil Wolfson, Cody Carroll
Introduction Ketamine Assisted Psychotherapy (KAP) is a developing modality with broad impact on humans suffering with a variety of emotional and relationship difficulties that encompass many diagnostic entities. Our application of KAP has extended to and included the treatment of adolescents and young adults in a family therapy format. Given the increasing scope and complexity of the...
Molecular Psychiatry
September 19, 2026
Dijia Wang, Junnan Xu, Zhaoran Wang et al.
Hallucinations are a core feature of several psychiatric disorders, but the circuit mechanisms that separate perception from behavioral output remain poorly defined. Here, we combined an auditory discrimination task with AI-based pose analysis to quantify S-ketamine-induced false auditory threat responses and behavioral disorganization in mice. Control assays, including sucrose preference, loss...